Masatsugu Numata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Masatsugu Numata has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Hirohito Tsubouchi
Department of Digestive and Life-Style Related Disease, Health Research Course, Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
13 shared publications - Akio Ido
Kagoshima University Graduate School of Medical and Dental Sciences
11 shared publications - Hitoshi Setoyama
Center for Education of Medical Residents, Kagoshima University Hospital, Kagoshima, Japan
7 shared publications Hiroshi Fujita
6 shared publications- Akihiro Moriuchi
Digestive Disease and Life-style Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences
5 shared publications Fumisato Sasaki
5 shared publications
Latest Publications
- 1 December 2014
- Vol. 111 (12) , 2311-8
Primary squamous cell carcinoma of the duodenum effectively treated with TS-1: a case report.
An 89-year-old man was admitted to our hospital for thorough investigation of refractory diabetes mellitus, which revealed primary squamous cell carcinoma of the duodenum. After two courses of chemotherapy, follow-up esophagoduodenogastroscopy and duodenal biopsy showed no evidence of tumor. No findings were suggestive of recurrence of the primary lesion 19 months after starting chemotherapy. This case suggests that chemotherapy including TS-1 may be effective for treating unresectable primary squamous cell carcinoma of the duodenum.
- 1 December 2014
- Vol. 111 (12) , 2311-8
Primary squamous cell carcinoma of the duodenum effectively treated with TS-1: a case report.
An 89-year-old man was admitted to our hospital for thorough investigation of refractory diabetes mellitus, which revealed primary squamous cell carcinoma of the duodenum. After two courses of chemotherapy, follow-up esophagoduodenogastroscopy and duodenal biopsy showed no evidence of tumor. No findings were suggestive of recurrence of the primary lesion 19 months after starting chemotherapy. This case suggests that chemotherapy including TS-1 may be effective for treating unresectable primary squamous cell carcinoma of the duodenum.
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB366
Su1554 Evaluation of Submucosal Fibrosis Using Endoscopic Ultrasonography Prior to Colorectal Endoscopic Submucosal Dissection
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB366
Su1554 Evaluation of Submucosal Fibrosis Using Endoscopic Ultrasonography Prior to Colorectal Endoscopic Submucosal Dissection
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB546
Tu1453 The Effect of Preoperative Biopsy on Colorectal Endoscopic Submucosal Dissection
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB546
Tu1453 The Effect of Preoperative Biopsy on Colorectal Endoscopic Submucosal Dissection
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1950 Hypertension Exacerbates Hepatic Fibrosis Induced by a Choline-Deficient L-Amino Acid-Defined Diet in Rats
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1950 Hypertension Exacerbates Hepatic Fibrosis Induced by a Choline-Deficient L-Amino Acid-Defined Diet in Rats
- Open Access
- 8 May 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 55
Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety
Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase I/II study of patients with fulminant hepatitis (FH) or late-onset hepatic failure (LOHF), in order to examine the safety, pharmacokinetics, and clinical efficacy of this molecule. Potential adverse effects identified through preclinical safety tests with rh-HGF include a decrease in blood pressure (BP) and an increase in urinary excretion of albumin. Therefore, we further investigated the effect of rh-HGF on circulatory status and renal toxicity in preclinical animal studies. In a clinical trial, 20 patients with FH or LOHF were evaluated for participation in this clinical trial, and four patients were enrolled. Subjects received rh-HGF (0.6 mg/m2/day) intravenously for 12 to 14 days. We established an infusion method to avoid rapid BP reduction in miniature swine, and confirmed reversibility of renal toxicity in rats. Although administration of rh-HGF moderately decreased BP in the participating subjects, this BP reduction did not require cessation of rh-HGF or any vasopressor therapy; BP returned to resting levels after the completion of rh-HGF infusion. Repeated doses of rh-HGF did not induce renal toxicity, and severe adverse events were not observed. Two patients survived, however, there was no evidence that rh-HGF was effective for the treatment of FH or LOHF. Intravenous rh-HGF at a dose of 0.6 mg/m2 was well tolerated in patients with FH or LOHF; therefore, it is desirable to conduct further investigations to determine the efficacy of rh-HGF at an increased dose.
- 8 May 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 55
Open AccessSafety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety
Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase I/II study of patients with fulminant hepatitis (FH) or late-onset hepatic failure (LOHF), in order to examine the safety, pharmacokinetics, and clinical efficacy of this molecule. Potential adverse effects identified through preclinical safety tests with rh-HGF include a decrease in blood pressure (BP) and an increase in urinary excretion of albumin. Therefore, we further investigated the effect of rh-HGF on circulatory status and renal toxicity in preclinical animal studies. In a clinical trial, 20 patients with FH or LOHF were evaluated for participation in this clinical trial, and four patients were enrolled. Subjects received rh-HGF (0.6 mg/m2/day) intravenously for 12 to 14 days. We established an infusion method to avoid rapid BP reduction in miniature swine, and confirmed reversibility of renal toxicity in rats. Although administration of rh-HGF moderately decreased BP in the participating subjects, this BP reduction did not require cessation of rh-HGF or any vasopressor therapy; BP returned to resting levels after the completion of rh-HGF infusion. Repeated doses of rh-HGF did not induce renal toxicity, and severe adverse events were not observed. Two patients survived, however, there was no evidence that rh-HGF was effective for the treatment of FH or LOHF. Intravenous rh-HGF at a dose of 0.6 mg/m2 was well tolerated in patients with FH or LOHF; therefore, it is desirable to conduct further investigations to determine the efficacy of rh-HGF at an increased dose.
- Open Access
- 4 May 2011
- Published by Spandidos Publications in Oncology Reports
- Vol. 26 (2) , 335-341
Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice
Hepatocyte growth factor (HGF), which facilitates the repair of injured mucosa, has the potential to be a new therapeutic agent for inflammatory bowel disease (IBD). However, given that the incidence of colorectal cancer increases continuously with disease duration in patients with IBD, the fact that HGF is a potent mitogen for intestinal epithelial cells may further heighten the risk of bowel cancer in this patient population. In this study, we examined the effects of recombinant HGF on colorectal cancer development in mice with or without experimentally induced colitis. Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. In a mouse model of colitis-associated cancer, colorectal cancer frequently developed despite only a single injection of AOM prior to three cycles of dextran sulfate sodium administration. However, HGF treatment significantly facilitated the repair of injured mucosa, leading to inhibition of colorectal cancer development in a dose-dependent manner. Thus, HGF-induced repair of injured mucosa inhibits rather than accelerates the development of colorectal cancer, and these results also suggest the importance of blocking the cycles of mucosal injury and repair to prevent colitis-associated colorectal cancer.
- 4 May 2011
- Published by Spandidos Publications in Oncology Reports
- Vol. 26 (2) , 335-341
Open AccessHepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice
Hepatocyte growth factor (HGF), which facilitates the repair of injured mucosa, has the potential to be a new therapeutic agent for inflammatory bowel disease (IBD). However, given that the incidence of colorectal cancer increases continuously with disease duration in patients with IBD, the fact that HGF is a potent mitogen for intestinal epithelial cells may further heighten the risk of bowel cancer in this patient population. In this study, we examined the effects of recombinant HGF on colorectal cancer development in mice with or without experimentally induced colitis. Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. In a mouse model of colitis-associated cancer, colorectal cancer frequently developed despite only a single injection of AOM prior to three cycles of dextran sulfate sodium administration. However, HGF treatment significantly facilitated the repair of injured mucosa, leading to inhibition of colorectal cancer development in a dose-dependent manner. Thus, HGF-induced repair of injured mucosa inhibits rather than accelerates the development of colorectal cancer, and these results also suggest the importance of blocking the cycles of mucosal injury and repair to prevent colitis-associated colorectal cancer.
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Hepatocyte Growth Factor Inhibits Colon Cancer Development in a Mouse Model of Ulcerative Colitis
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Hepatocyte Growth Factor Inhibits Colon Cancer Development in a Mouse Model of Ulcerative Colitis
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -742-742
W1796 P62/Sqstm1 May Be Useful for Assessment of Autophagic Status in Macrophages and Granulomas of Crohn's Disease
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -742-742
W1796 P62/Sqstm1 May Be Useful for Assessment of Autophagic Status in Macrophages and Granulomas of Crohn's Disease
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1825 Repeated Enemas of Recombinant Human Hepatocyte Growth Factor Ameliorate Rat Experimental Colitis Without Increasing Serum HGF Levels
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1825 Repeated Enemas of Recombinant Human Hepatocyte Growth Factor Ameliorate Rat Experimental Colitis Without Increasing Serum HGF Levels
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-800-800
M1869 A Phase I/II Study of Recombinant Human Hgf (Rh-Hgf) for the Treatment of Fulminant Hepatic Failure: A Safety Evaluation in Four Subjects Who Were Administered Repeated Doses of Rh-Hgf
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-800-800
M1869 A Phase I/II Study of Recombinant Human Hgf (Rh-Hgf) for the Treatment of Fulminant Hepatic Failure: A Safety Evaluation in Four Subjects Who Were Administered Repeated Doses of Rh-Hgf